Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapy-related myeloid neoplasms: when genetics and environment collide
Megan E. McNerney, Lucy A. Godley, Michelle M. Le Beau
Nature reviews. Cancer (2017) Vol. 17, Iss. 9, pp. 513-527
Open Access | Times Cited: 341

Showing 1-25 of 341 citing articles:

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, et al.
Blood (2022) Vol. 140, Iss. 12, pp. 1345-1377
Open Access | Times Cited: 1738
Acute myeloid leukaemia
Nicholas J. Short, Michael Rytting, Jorge E. Cortés
The Lancet (2018) Vol. 392, Iss. 10147, pp. 593-606
Open Access | Times Cited: 662
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton, Ryan Ptashkin, Teng Gao, et al.
Nature Genetics (2020) Vol. 52, Iss. 11, pp. 1219-1226
Open Access | Times Cited: 546
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, et al.
NEJM Evidence (2022) Vol. 1, Iss. 7
Closed Access | Times Cited: 522
Advances in acute myeloid leukemia
Laura F. Newell, Rachel J. Cook
BMJ (2021), pp. n2026-n2026
Open Access | Times Cited: 304
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Valsamo Anagnostou, Patrick M. Forde, James R. White, et al.
Cancer Research (2018) Vol. 79, Iss. 6, pp. 1214-1225
Open Access | Times Cited: 265
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017
Ying Dong, Oumin Shi, Quan-Xiang Zeng, et al.
Experimental Hematology and Oncology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 249
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017
Ming Yi, Anping Li, Linghui Zhou, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 195
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
Pierre‐Marie Morice, Alexandra Léary, Charles Dolladille, et al.
The Lancet Haematology (2020) Vol. 8, Iss. 2, pp. e122-e134
Closed Access | Times Cited: 194
NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps
José M. Adrover, Sheri A. C. McDowell, Xue‐Yan He, et al.
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 505-526
Open Access | Times Cited: 138
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Olga K. Weinberg, Alexa J. Siddon, Yazan F. Madanat, et al.
Blood Advances (2022) Vol. 6, Iss. 9, pp. 2847-2853
Open Access | Times Cited: 130
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
Adam S. Sperling, Veronica Guerra, James A. Kennedy, et al.
Blood (2022) Vol. 140, Iss. 16, pp. 1753-1763
Open Access | Times Cited: 93
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
Elias Jabbour, Nicholas J. Short, Jayastu Senapati, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 6, pp. e433-e444
Closed Access | Times Cited: 56
Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era
Lindsay M. Morton, Graça M. Dores, Sara J. Schonfeld, et al.
JAMA Oncology (2018) Vol. 5, Iss. 3, pp. 318-318
Open Access | Times Cited: 159
Acute Myeloid Leukemia: The Good, the Bad, and the Ugly
Andrew Kuykendall, Nicolas Duployez, Nicolas Boissel, et al.
American Society of Clinical Oncology Educational Book (2018), Iss. 38, pp. 555-573
Closed Access | Times Cited: 101
FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity
Vijayashree Mysore, Xavier Culleré, Joseph Mears, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 83
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
Teng Gao, Ryan Ptashkin, Kelly L. Bolton, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 82
An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States
Taisen Hao, Min Li-Talley, Alison Buck, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 79
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Khanh Do, Bose Kochupurakkal, Sarah Kelland, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4710-4716
Open Access | Times Cited: 72
Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis
Goodwin G. Jinesh, Andrew S. Brohl
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 58
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Carmelo Gurnari, Simona Pagliuca, Pedro Henrique Prata, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 1, pp. 132-142
Closed Access | Times Cited: 56
Diagnosis and treatment of therapy-related acute myeloid leukemia
Stephen A. Strickland, Norbert Vey
Critical Reviews in Oncology/Hematology (2022) Vol. 171, pp. 103607-103607
Open Access | Times Cited: 54
An overview of chemotoxicity and radiation toxicity in cancer therapy
Victor Yazbeck, Erin R. Alesi, Jennifer S. Myers, et al.
Advances in cancer research (2022), pp. 1-27
Closed Access | Times Cited: 39
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
Brunangelo Falini, Maria Paola Martelli
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 481-492
Closed Access | Times Cited: 34
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
Mehmet Samur, Marco Roncador, Anıl Aktaş Samur, et al.
Blood (2023) Vol. 141, Iss. 14, pp. 1724-1736
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top